American Strategic Income Portfolio I (ASP)

10.34
Prev Close 10.28
Day Low/High 10.30 / 10.43
52 Wk Low/High 8.70 / 10.43
Avg Volume 9.50K
Exchange
Shares Outstanding 4.23M
Market Cap 43.77M
Div & Yield 0.66 (6.40%)

Latest News

Acerus Provides Update On Temporary Unavailability Of NATESTO® In Canada And South Korea

Acerus Provides Update On Temporary Unavailability Of NATESTO® In Canada And South Korea

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO ® in Canada and South Korea, following the previous announcement of the voluntary replacement of certain NATESTO ® lots released...

Acerus Pharma Hosting Key Opinion Leader Meeting On Unique Clinical Evidence Of NATESTO® For Treatment Of Hypogonadism

Acerus Pharma Hosting Key Opinion Leader Meeting On Unique Clinical Evidence Of NATESTO® For Treatment Of Hypogonadism

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO ® for the treatment of hypogonadism on Wednesday, October 30...

New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO ® Spermatogenesis Study as part of the "Late Breaking" Abstract Session at the 75th Annual American Society for Reproductive Medicine...

New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months

- NATESTO® shown to significantly increase mean testosterone levels, while maintaining sufficient gonadotropins to preserve fertility

Acerus Announces Amendment To Credit Agreement And Waiver Of Certain Q3 Financial Covenants

Acerus Announces Amendment To Credit Agreement And Waiver Of Certain Q3 Financial Covenants

Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC ("SWK") and that it received a waiver letter from...

Acerus Announces Temporary Unavailability Of NATESTO® In Canada And South Korea

Acerus Announces Temporary Unavailability Of NATESTO® In Canada And South Korea

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO ® lots released in the Canadian and South Korean markets, which is expected to cause temporary shortages in those markets.

Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States

Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States

- Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives

Acerus And Aytu Bioscience To Co-promote Natesto® In The United States

Acerus And Aytu Bioscience To Co-promote Natesto® In The United States

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO ® in the U.

Acerus To Report Second Quarter 2019 Financial Results And Host Investor Call

Acerus To Report Second Quarter 2019 Financial Results And Host Investor Call

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens.

Acerus Congratulates US Partner Aytu Bioscience On Listing Of NATESTO® On National Pharmacy Benefit Manager's Formulary

Acerus Congratulates US Partner Aytu Bioscience On Listing Of NATESTO® On National Pharmacy Benefit Manager's Formulary

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) ("Acerus" or the "Company") announced today that NATESTO ® (testosterone nasal gel) is now on formulary and covered nationwide by a leading national pharmacy benefit manager (PBM) in the United...

Acerus Announces Closing Of US$5 Million Secured Term Loan

Acerus Announces Closing Of US$5 Million Secured Term Loan

Acerus Pharmaceuticals Corporation (the "Company" or "Acerus") (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility ("the Loan") with First Generation Capital Inc.

Acerus Provides Business Update On NATESTO®

Acerus Provides Business Update On NATESTO®

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) ("Acerus" or the "Company") announced today an update relative to the Company's NATESTO ® business.

Acerus Announces Publication Of Study Results Demonstrating Effectiveness Of NATESTO® Regardless Of Baseline Symptom Severity

Acerus Announces Publication Of Study Results Demonstrating Effectiveness Of NATESTO® Regardless Of Baseline Symptom Severity

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) ("Acerus" or the "Company") announced today the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO ® achieves similar symptom improvement, regardless...

Acerus Announces Amendment To Term Loan Credit Facility

Acerus Announces Amendment To Term Loan Credit Facility

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) ("Acerus" or the "Company") today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC ("SWK").

Acerus Announces Voting Results For The 2019 Annual Meeting

Acerus Announces Voting Results For The 2019 Annual Meeting

TORONTO, June 27, 2019 /CNW/ - Acerus Pharmaceuticals Corporation (" Acerus") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario.

Acerus Provides Update On Avanafil Health Canada Submission

Acerus Provides Update On Avanafil Health Canada Submission

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) ("Acerus" or the "Company") today announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission ("NDS") for avanafil.

Acerus Reaches Mutual Agreement With Innovus Pharma To Terminate Distribution And License Agreement For UriVarx® In Canada

Acerus Reaches Mutual Agreement With Innovus Pharma To Terminate Distribution And License Agreement For UriVarx® In Canada

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) ("Acerus" or the "Company") today announced that it has reached a mutual agreement with Innovus Pharmaceuticals, Inc.

Acerus Signs License Agreement To Nasal Technology With University Of Texas At Austin

Acerus Signs License Agreement To Nasal Technology With University Of Texas At Austin

Acerus Pharmaceuticals Corporation ("Acerus" or "the Company") (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the "PLA") with the University of Texas at Austin for technology related to the nasal administration of...

Acerus Reports First Quarter 2019 Financial Results

Acerus Reports First Quarter 2019 Financial Results

Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three-month period ended March 31, 2019 ("Q1-2019).

Acerus Approved To Trade On The OTCQB Venture Market Under The Symbol ASPCF

Acerus Approved To Trade On The OTCQB Venture Market Under The Symbol ASPCF

Acerus Pharmaceuticals Corporation ("Acerus" or "the Company") (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB Venture Market and will trade under the symbol "ASPCF" effective immediately.

Acerus Engages Paradigm Capital To Pursue Cannabinoid Opportunities

Acerus Engages Paradigm Capital To Pursue Cannabinoid Opportunities

Acerus Pharmaceuticals Corporation (TSX:ASP) ("Acerus" or the "Company") today announced that it has engaged Paradigm Capital Inc.

Acerus Secures CDN$1.6 Million Of New NATESTO® Orders From Its U.S. Licensee Aytu Bioscience

Acerus Secures CDN$1.6 Million Of New NATESTO® Orders From Its U.S. Licensee Aytu Bioscience

Acerus Pharmaceuticals Corporation (TSX:ASP) today announced CDN $1.

Acerus Acquires Canadian Rights To GYNOFLOR™

Acerus Acquires Canadian Rights To GYNOFLOR™

Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that it has entered into a license and supply agreement with Medinova AG, a Swiss pharmaceutical company, granting Acerus the exclusive rights to commercialize...

Acerus Reports Approval Of ESTRACE® Generic In Canada

Acerus Reports Approval Of ESTRACE® Generic In Canada

Acerus Pharmaceuticals Corporation (TSX:ASP) today reported that Health Canada has granted a Notice of Compliance (NOC) for a generic version of ESTRACE ®.

What You Want Isn't What You Need

What You Want Isn't What You Need

U.S. large-cap stocks face significant headwinds. 

Nuveen Announces Additions To Closed-End Fund Product Line

Nuveen Announces Additions To Closed-End Fund Product Line

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced the addition of several closed-end funds to the Nuveen platform.